Trademark applications and grants for Gw Pharma Limited. Gw Pharma Limited has 26 trademark applications. The latest application filed is for "EPIDIALOGUES"
State Incorporated | UNITED KINGDOM |
Entity Type | CORPORATION |
Address | Sovereign House, Vision Park Chivers Way, Histon Cambridge UNITED KINGDOM CB249BZ |
Patent Application | Date |
---|---|
USE OF CANNABIDIOL IN COMBINATION WITH ANTIBIOTICS 20220183997 - 17/435892 GUY; Geoffrey ;   et al. | 2022-06-16 |
PHARMACEUTICAL FORMULATION 20210221587 - 17/060700 Whittle; Brian Anthony | 2021-07-22 |
EXTRACTION OF PHARMACEUTICALLY ACTIVE COMPONENTS FROM PLANT MATERIALS 20210128657 - 16/904643 WHITTLE; BRIAN ANTHONY ;   et al. | 2021-05-06 |
USE OF THE PHYTOCANNABINOID CANNABIDIVARIN (CBDV) IN THE TREATMENT OF EPILEPSY 20210100755 - 17/012448 WHALLEY; Ben ;   et al. | 2021-04-08 |
CANNABINOIDS IN COMBINATION WITH NON-CANNABINOID CHEMOTHERAPEUTIC AGENTS 20210069333 - 17/102109 VELASCO DIEZ; Guillermo ;   et al. | 2021-03-11 |
NCAGE Code | U1FF3 | GW PHARMA LIMITED |
CAGE Code | U1FF3 | GW PHARMA LIMITED |
uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.
While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.
All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.